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Sir,
Staphylococcus pseudintermedius is the most frequent causative
agent of canine pyoderma and may also be associated with
wound infections, urinary tract infections and otitis externa in
dogs.1 Although more rarely, S. pseudintermedius causes infec-
tions in cats and has also been identified in infections of
humans.1 – 3 The latter observation highlights the zoonotic poten-
tial of S. pseudintermedius. S. pseudintermedius appears to be
able to readily accumulate antimicrobial resistance genes1,4
and, in recent years, a rapid increase in methicillin resistance
has been observed.5,6 A recent multicentre study on methicillin-
resistant S. pseudintermedius (MRSP) of canine origin, obtained in
different European countries as well as in the USA and Canada,
revealed that most of the canine strains exhibited resistance to
virtually all classes of antimicrobial agents approved for veteri-
nary use.4 This represents a major therapeutic challenge for
veterinarians in Europe and North America. Moreover, this multi-
centre study revealed that among MRSP from dogs two distinct,
dominant clones—as identified by multilocus sequence typing
(MLST), spa typing, SCCmec typing and SmaI PFGE—have dissem-
inated across Europe and North America.4 In contrast to the
wealth of data available for MRSP isolates of canine origin, little
data are available about MRSP from cats.
The aim of the present study was to characterize MRSP iso-
lates from cats in different countries for their genetic relation-
ships and antimicrobial resistance phenotypes and genotypes.
Twelve epidemiologically unrelated MRSP isolates of feline
origin were identified during 2006–08 in five different countries
(Table 1). Eleven isolates were from clinical disease conditions,
including septicaemia, urinary tract infections, nephritis, rhinitis,
wound infection and pneumonia. The remaining isolate was
obtained from a nasal swab of an apparently healthy cat
(Table 1). All isolates were confirmed to be S. pseudintermedius
by MboI digestion of a PCR-amplified internal fragment of the
pta gene.4 For a better comparison with data of canine MRSP iso-
lates, MLST,7 spa typing,8 SmaI PFGE and SCCmec typing was per-
formed as recently described.4 MICs of 17 antimicrobial agents
were determined using the VetMICTM microdilution panels
(National Veterinary Institute, Uppsala, Sweden) as previously
described and evaluated using the breakpoints of the CLSI.4
MICs of rifampicin, mupirocin and quinupristin/dalfopristin were
determined by Etestw (AB Biodisk, Solna, Sweden). Antibiotic
resistance genes were detected using either a microarray or
specific PCR assays as described previously.4
All 12 feline S. pseudintermedius proved to be MRSP by oxacil-
lin MICs of.16 mg/L and carriage of the mecA gene. Despite the
diverse geographical origins, the 11 European MRSP isolates
shared the same MLST type ST71, spa type t02 and SCCmec
type II–III. SCCmec type II–III is a hybrid of SCCmec II (2A)
from Staphylococcus epidermidis and SCCmec III from
Staphylococcus aureus.9 PFGE analysis identified three different
patterns J, N and O among these European feline MRSP isolates.
The single MRSP isolate from Canada harboured an SCCmec type
V element and exhibited spa type t23, MLST type ST100 and PFGE
pattern B. A comparison with the data of the multicentre study
on MRSP in dogs4 revealed that PFGE patterns B, N and O were
exclusive to feline MRSP isolates whereas pattern J was the
dominant PFGE pattern among European canine MRSP.4 The
Canadian feline MRSP isolate also differed largely in its resistance
phenotype and genotype from the European feline MRSP isolates.
It was only resistant to b-lactam antibiotics via mecA and blaZ,
and to tetracyclines via tet(M). In contrast, the European isolates
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Table 1. Characteristics of the 12 MRSP isolates from cats investigated in this study
Isolate no. Countrya Disease condition
SCCmec
type spa type MLST type
PFGE
pattern Resistance phenotypeb Resistance genotype
E028 I septicaemia II–III t02 ST71 J BLA, TET, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), catpC221, dfrG,
aac(6′)-Ie/aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E029 I nephritis II–III t02 ST71 N BLA, TET, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), catpC221, dfrG,
aac(6′)-Ie/aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E031 I septicaemia II–III t02 ST71 J BLA, TET, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), catpC221, dfrG,
aac(6′)-Ie/aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E037 I septicaemia II–III t02 ST71 J BLA, TET, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), catpC221, dfrG,
aac(6′)-Ie/aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E047 CH rhinitis II–III t02 ST71 J BLA, TET, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), catpC221, dfrG,
aac(6’)-Ie/aph(2’)-Ia, aph(3’)-III, ant(6’)-Ia
E051 CH wound infection II–III t02 ST71 J BLA, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, erm(B), catpC221, dfrG, aac(6′)-Ie/
aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E053 CH urinary tract infection II–III t02 ST71 J BLA, TET, ML, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), dfrG, aac(6′)-Ie/
aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E060 CH urinary tract infection II–III t02 ST71 J BLA, TET, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), catpC221, dfrG,
aac(6′)-Ie/aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E072 CH urinary tract infection II–III t02 ST71 J BLA, TET, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), catpC221, dfrG,
aac(6’)-Ie/aph(2’)-Ia, aph(3’)-III, ant(6’)-Ia
E076 NL urinary tract infection II–III t02 ST71 O BLA, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, erm(B), catpC221, dfrG, aac(6′)-Ie/
aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E114 D healthy II–III t02 ST71 J BLA, TET, ML, CHL, TMP, GEN, KAN, STR, FQ mecA, blaZ, tet(K), erm(B), catpC221, dfrG,
aac(6′)-Ie/aph(2′)-Ia, aph(3′)-III, ant(6′)-Ia
E132 CAN pneumonia V t23 ST100 B BLA, TET mecA, blaZ, tet(M)
aI, Italy; CH, Switzerland; NL, the Netherlands; D, Germany; CAN, Canada.
bBLA, b-lactam antibiotics; CHL, chloramphenicol; FQ, fluoroquinolones; GEN, gentamicin; KAN, kanamycin; ML, macrolides/lincosamides; STR, streptomycin; TET, tetracyclines;
TMP, trimethoprim.
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exhibited three different expanded resistance phenotypes and
genotypes (Table 1). All isolates were resistant to b-lactam anti-
biotics (mecA, blaZ), macrolides/lincosamides [erm(B)], gentami-
cin/kanamycin [aac(6′)-Ie/aph(2′)-Ia], kanamycin [aph(3′)-III],
streptomycin [ant(6′)-Ia], trimethoprim [dfrG] and ciprofloxacin.
Moreover, all but one isolate from Switzerland and all but two
isolates from Switzerland and the Netherlands were resistant
to chloramphenicol (catpC221) and to tetracyclines [tet(K)],
respectively. However, all feline MRSP isolates were susceptible
to mupirocin, rifampicin, quinupristin/dalfopristin, linezolid and
vancomycin, which are important for decolonization of humans
or represent ‘antimicrobial agents of last resort’ for the treat-
ment of methicillin-resistant S. aureus (MRSA) infections in
humans.
A comparison with the results of the genetic analysis of
canine MRSP showed that the Canadian feline MRSP differed in
all characteristics, except SCCmec type V, from the dominant
canine MRSP clone in North America, which is characterized by
ST68 (MLST)–C (PFGE)–t06 (spa)–V (SCCmec).4 In contrast, 9 of
the 11 European feline MRSP isolates were identified as
members of the previously described dominant clonal lineage
among canine MRSP in Europe, which is characterized by ST71
(MLST)–J (PFGE)–t02 (spa)–II–III (SCCmec).4 This observation
strongly suggested an exchange of MRSP isolates between
dogs and cats in Europe. Whether the feline MRSP isolate from
Canada represents a member of a new MRSP clone with a par-
ticular tropism for cats remains to be determined.
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Sir,
Previous studies performed in a large number of Belgian hospi-
tals showed the dissemination of a major clone of the virulent
B2 group O25b:H4-ST131 CTX-M-15-producing Escherichia coli.1
This E. coli ST131 clone has been reported worldwide and rep-
resents a major public health problem.2 The present study
sought to characterize blaCTX-M-15-containing plasmids associ-
ated with ST131 E. coli CTX-M-15 isolates recovered in Belgian
hospitals. This specific clone was detected from clinical speci-
mens of patients hospitalized at the Erasme hospital in Brus-
sels since 2001, as well as in 18 other Belgian hospitals
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